BIVI BioVie Pharma: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik BioVie Inc. (BIVI)

BioVie Inc. possesses high scientific authority in the therapy of liver pathologies. Its capitalization relies on the development of treatments for Alzheimer's and cirrhosis. The company is currently seeking a strategic partner for survival following test failures. The historical EV/Sales trend visualizes capital inflow dynamics, where 0.00 shows the current enterprise value-to-revenue valuation metric.

BioVie Inc (BIVI) - Multiplikator EV/Sales saka 23.11.2025 nganti 20.11.2026

Rincian metrik keuangan lan pasar BioVie (BIVI)

- rega pasar lan target rega analis:
Pambiji fundamental perusahaan:BIVI (BioVie Pharma)
Barang utama biovieinc.com

BioVie Inc. is tapping into the colossal dementia and cirrhosis therapy market, focusing on the innovative suppression of neuroinflammation. This EV-to-sales multiple compares the total enterprise value of the business with its revenue excluding debt, allowing investors to assess the real market value of assets relative to operating income and timely identify the risk of undervaluation or overpayment when analyzing the chart.